10111222Developing a transformative pan-cancer drug that unleashes the true potential of I/OClosedCollaborative R&DInnovate UKImmunotherapies, in which the body's immune system is activated to fight the tumour, have been the biggest breakthrough in cancer therapy for decades. Previously invariably deadly cancers, such as metastatic melanoma, can now be cured. However, amongst the ~20 different types of cancer for which these therapies (so-called checkpoint inhibitors and CAR-T cells) have been approved, true long-term cures have remained rare. MomentousTx develops a new drug that will unlock the real potential for cancer immunotherapies, extending groundbreaking efficacy and potential cures to many more patients and more types of cancer. The new drug targets a very fundamental mechanism, discovered at Cambridge University, which is relevant across most types of cancer.